We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current REXN market cap is 40.97M. The company's latest EPS is USD -0.4411 and P/E is -4.10.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 39.85M | 1.75M | 3.67M | 11.94M |
| Operating Income | -4.54M | 34.21M | -6.13M | -5.39M | 6.39M |
| Net Income | -4.53M | 33.94M | -5.79M | -4.96M | 5.56M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 589k | 39.85M | 19.05M |
| Operating Income | -11.22M | -19.97M | -22.71M | 18.23M | -10.56M |
| Net Income | -8.64M | -24.62M | -56.69M | 17.89M | -9.99M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 14.57M | 48.99M | 45.4M | 43.47M | 54.19M |
| Total Liabilities | 2.69M | 2.75M | 4.15M | 5.76M | 3.91M |
| Total Equity | 11.88M | 46.24M | 41.25M | 37.7M | 50.28M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 12.97M | 17.68M | 26.08M | 48.99M | 53.95M |
| Total Liabilities | 3.01M | 31.15M | 3.86M | 2.75M | 4.04M |
| Total Equity | 9.96M | -13.47M | 22.22M | 46.24M | 49.91M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -14.48M | 14.31M | -3.65M | -2.66M | -5.66M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 3.8M | 3.79M | N/A | N/A | 5.38M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.28M | -6.8M | -19.37M | 14.31M | -1.11M |
| Investing | 3.1M | 539k | -100k | N/A | N/A |
| Financing | 7.65M | 21.12M | 27.61M | 3.79M | 8.98M |
| Market Cap | 40.97M |
| Price to Earnings Ratio | -4.10 |
| Price to Sales Ratio | 2.15 |
| Price to Cash Ratio | 0.81 |
| Price to Book Ratio | 0.82 |
| Dividend Yield | - |
| Shares Outstanding | 22.64M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.08 (4.37%) |
| Company Name | Rexahn Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.ocuphire.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
